Manufacturing

Articles

Under a collaboration, IDT Biologika and Exothera will conduct feasibility studies on scaling up the manufacturing process for viral vector-based vaccines.

IDT Biologika and Exothera Partner on Viral Vaccines Manufacturing

Pfizer and BioNTech receive positive opinion for COVID-19 vaccine booster in adolescents 12 through 17 years of age in the EU. 

EMA Issues Positive Opinion on Pfizer and BioNTech COVID-19 Vaccine Booster in Adolescents 12 Through 17 Years of Age in EU

Scottish Enterprise has awarded £20 million (US$27 million) to Valneva Scotland to advance vaccine development.

Valneva Awarded R&D Funding by Scottish Enterprise for Vaccine Development

Alvea has begun preclinical testing of a scalable, shelf-stable DNA vaccine against SARS-CoV-2 variants.

Alvea to Develop New DNA Vaccine Against SARS-CoV-2 Variants

Moderna and Thermo Fisher Scientific have formed a collaboration to leverage dedicated commercial fill/finish manufacturing capacity in the US for mRNA vaccines and therapies.

Moderna and Thermo Fisher Scientific Form Long-Term Strategic Manufacturing Collaboration

Recipharm has strengthened its biologics manufacturing capabilities with the acquisition of both Vibalogics and Arranta Bio.

Recipharm Acquires Two Biologics CDMOs: Vibalogics and Arranta Bio

Thermo Fisher Scientific is expanding its Millersburg, Penn., site with a $40 million investment to support increased production of single-use technology for critical vaccines and biologics.

Thermo Fisher Scientific Invests $40 Million to Expand Bioprocessing Manufacturing Site

Meg Rivers is the former senior editor for 

Chris Spivey is director of Industry Relations and Strategic Partnership, MJH Life Sciences.

Podcasts

In this episode of the Drug Solutions Podcast, Chris Spivey, editorial director, and Meg Rivers, senior editor, interview Sean Tucker, PhD, chief scientific officer of Vaxart, on developing oral recombinant vaccines.

Drug Solutions Podcast: Developing Oral Recombinant Vaccines

Arranta Bio will use Cytiva’s FlexFactory single-use manufacturing platform to produce mRNA vaccines.

Cytiva Provides Arranta Bio with Single-Use Manufacturing Platform for mRNA Products

Hallie Forcinio is packing editor for Pharmaceutical Technology and Pharmaceutical Technology Europe, editorhal@sbcglobal.net.

Protective external packaging ensures COVID-19 vaccines arrive safely. 

Manufacturing, Vaccines